Log in to your Inderes Free account to see all free content on this page.
Scibase Holding
0.43 SEK 0%39 investors are following this company
SciBase Holding is a medical technology company. The Group specializes in the management of cancer diagnostics, mainly focused on the treatment and detection of various melanomas. The company has developed an electric handheld probe that analyzes the measurement signal to detect specific changes in the body's skin tissue. The head office is located in Stockholm.
P/E (24e)
-1.5
EV/EBIT (adj.) (24e)
-1.5
P/B (24e)
3.81
Dividend yield-% (24e)
-
Target price
0.32 SEK
Recommendation
Reduce
Updated
3.6.2024
First North Stockholm
SCIB
Daily low / high price
0.38 / 0.55
SEK
Market cap
94.4M SEK
Turnover
707K SEK
Volume
1.7M
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
![Antti Luiro Antti Luiro](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://core.inderes.fi/sites/default/files/2023-08/Antti_Luiro.jpg)
Antti Luiro
Head of Nordic ER Development, Analyst
Financial calendar
Interim report
21.08.2024
Interim report
12.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Gell Group | 11.0 % | 11.0 % |
Avanza Pension | 9.7 % | 9.7 % |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 9.5 | 11.7 | 17.9 | 23.2 | 31.2 | 47.6 | 77.1 | 122.5 |
growth-% | 2.6 % | 23.2 % | 52.6 % | 29.9 % | 34.4 % | 52.5 % | 61.9 % | 58.9 % |
EBITDA | -32.2 | -38.7 | -42.8 | -50.6 | -53.1 | -44.2 | -25.9 | 3.7 |
EBIT (adj.) | -34.8 | -41.6 | -46.4 | -53.9 | -56.4 | -47.2 | -29.1 | 0.3 |
EBIT | -34.8 | -41.6 | -46.4 | -53.9 | -56.4 | -47.2 | -29.1 | 0.3 |
Profit before taxes | -35.0 | -41.8 | -43.2 | -53.9 | -53.3 | -47.7 | -29.6 | -0.2 |
Net income | -35.0 | -41.8 | -43.2 | -53.9 | -53.3 | -47.7 | -29.6 | -0.2 |
EPS (adj.) | -1.12 | -0.67 | -0.63 | -0.50 | -0.29 | -0.22 | -0.13 | -0.00 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Login required
This content is only available for logged in users
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -337.7 % | -329.6 % | -239.1 % | -217.5 % | -170.0 % | -92.7 % | -33.5 % | 3.0 % |
EBIT-% (adj.) | -365.2 % | -354.8 % | -259.5 % | -232.0 % | -180.7 % | -99.1 % | -37.7 % | 0.2 % |
EBIT-% | -365.2 % | -354.8 % | -259.5 % | -232.0 % | -180.7 % | -99.1 % | -37.7 % | 0.2 % |
ROE | -88.7 % | -71.0 % | -89.9 % | -158.0 % | -157.3 % | -5,258.7 % | 78.4 % | 0.5 % |
ROI | -88.2 % | -70.7 % | -96.7 % | -158.0 % | -166.5 % | -171.3 % | -75.7 % | 0.4 % |
Login required
This content is only available for logged in users
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (SEK) | 4.48 | 5.36 | 3.71 | 0.83 | 0.43 | 0.43 | 0.43 | 0.43 |
Shares | 54.8 | 68.5 | 68.5 | 119.8 | 219.5 | 219.5 | 219.5 | 219.5 |
Market cap | 245.6 | 366.9 | 253.9 | 99.9 | 94.4 | 94.4 | 94.4 | 94.4 |
Enterprise value | 204.2 | 301.3 | 235.1 | 65.8 | 84.7 | 138.1 | 177.9 | 194.2 |
EV/S | 21.4 | 25.7 | 13.1 | 2.8 | 2.7 | 2.9 | 2.3 | 1.6 |
EV/EBITDA | - | - | - | - | - | - | - | 52.1 |
EV/EBIT (adj.) | - | - | - | - | - | - | - | 775.8 |
EV/EBIT | - | - | - | - | - | - | - | 775.8 |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 5.2 | 5.2 | 10.1 | 2.3 | 3.8 | - | - | - |
P/S | 25.8 | 31.3 | 14.2 | 4.3 | 3.0 | 2.0 | 1.2 | 0.8 |
Dividend yield | ||||||||
Equity ratio | 79.1 % | 82.8 % | 50.6 % | 66.9 % | 47.3 % | -33.8 % | -52.1 % | -35.3 % |
Gearing ratio | -88.4 % | -92.7 % | -74.6 % | -79.2 % | -39.0 % | -190.7 % | -159.1 % | -189.3 % |
Login required
This content is only available for logged in users
Quarter data
Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24 | Q2/24e | Q3/24e | Q4/24e | 2024e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 5.1 | 7.2 | 5.8 | 23.2 | 6.1 | 7.3 | 9.1 | 8.7 | 31.2 |
EBITDA | -12.8 | -12.0 | -15.7 | -50.6 | -13.4 | -14.0 | -12.7 | -12.9 | -53.1 |
EBIT | -13.8 | -12.7 | -16.6 | -53.9 | -14.3 | -14.9 | -13.5 | -13.8 | -56.4 |
Profit before taxes | -13.8 | -12.7 | -16.6 | -53.9 | -10.9 | -15.0 | -13.6 | -13.9 | -53.3 |
Net income | -13.8 | -12.7 | -16.6 | -53.9 | -10.9 | -15.0 | -13.6 | -13.9 | -53.3 |
Login required
This content is only available for logged in users
ShowingAll content types
SciBase partner with a large health care group in Los Angeles, Unified Health, and receives a first order
SciBase welcomes new chairman and thanks the former
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Annual general meeting has been held in SciBase Holding AB (publ)
SciBase strengthens the US organization with experienced leader in dermatology
![SciBase: Building faster growth takes time](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/546a3302-f056-45d5-9957-11ead5ab01d5.png)
SciBase: Building faster growth takes time
Redeye: Scibase - Stepping up the pace
SciBase: Interim report
SciBase: Today is the first day of trading in the new shares and warrants of series TO 2 issued in connection with the completed capital raising
SciBase already received first order from Austria
SciBase receives first order in Austria
SciBase Announces the launch of eBarrier Score, the First AI-Driven Skin Barrier Assessment tool for research and Cosmetic Testing
![SciBase Q1’24 preview: Still modest growth as US ramp-up is gathering speed](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/d2087f10-cc7c-4f60-9099-06a80ba4a818.png)